Skip to main content
SpringerLink
Log in

ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II–IV Melanoma Patients and Their Clinicians

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Livingstone A, Agrawal A, Stockler MR, Menzies AM, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07963-y.

    Article  PubMed  Google Scholar 

  2. Gershenwald JE, Hess KR, Sondak VK, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

    Google Scholar 

  3. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.

    Article  CAS  Google Scholar 

  4. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018; 378(19):1789–1801.

    Article  CAS  Google Scholar 

  5. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia

    Ann Livingstone RN MHSM GradDipHlthEc & Rachael L. Morton MScMed (Clin Epi) (Hons) PhD

  2. School of Public Health, The University of Sydney, Camperdown, Australia

    Ann Livingstone RN MHSM GradDipHlthEc

  3. Melanoma Institute Australia, The University of Sydney, Camperdown, NSW, Australia

    Rachael L. Morton MScMed (Clin Epi) (Hons) PhD

Authors
  1. Ann Livingstone RN MHSM GradDipHlthEc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachael L. Morton MScMed (Clin Epi) (Hons) PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann Livingstone RN MHSM GradDipHlthEc.

Ethics declarations

Disclosures

The authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This ASO Author Reflections is a brief invited commentary on the article “Preferences for Immunotherapy in Melanoma: a Systematic Review,” Ann Surg Oncol. (2019). https://doi.org/10.1245/s10434-019-07963-y.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Livingstone, A., Morton, R.L. ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II–IV Melanoma Patients and Their Clinicians. Ann Surg Oncol 27, 585–586 (2020). https://doi.org/10.1245/s10434-019-08020-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-08020-4

Search

Navigation